Home › Companies › Praxis Precision Medicines, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Praxis Precision Medicines, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 10, 2026: 5 items on Praxis Precision Medicines, Inc.’s Form 8-K, filed June 12, 2026: 2 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2024-2025 2025-2026
Explore Praxis Precision Medicines, Inc. in the interactive database Compare manager voting policies
These tallies are Praxis Precision Medicines, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Gregory Norden | 24,597,327 | -- | -- | 310,937 | 1,815,967 | 99% | Not verified | — |
| Elect Director: Marcio Souza | 24,771,396 | -- | -- | 136,868 | 1,815,967 | 99.4% | Not verified | — |
| Elect Director: William Young | 21,293,535 | -- | -- | 3,614,729 | 1,815,967 | 85% | Not verified | — |
| 2. Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm | 26,667,376 | 39,285 | 17,570 | -- | 0 | 99.8% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 24,054,017 | 824,318 | 29,929 | -- | 1,815,967 | 97% | Approved | — |
Source: Praxis Precision Medicines, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.
Each item below shows how the 303 asset managers that disclosed a Praxis Precision Medicines, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Gregory Norden
Praxis Precision Medicines, Inc.’s own tally for this item (“Elect Director: Gregory Norden”): 24,597,327 for, 310,937 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 90 asset managers below reported 9,284,367 for, 53,032 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,248,556 | 0 | 0 | 0 | For |
| Vanguard | 2,028,472 | 0 | 0 | 3,755 | For |
| BlackRock | 1,179,030 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,105,598 | 0 | 0 | 0 | For |
| T. Rowe Price | 559,689 | 0 | 0 | 0 | For |
| State Street | 333,482 | 0 | 0 | 0 | For |
| Charles Schwab | 216,365 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 211,007 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 140,900 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 120,135 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 119,129 | 0 | 0 | 0 | For |
| Equitable | 69,241 | 0 | 0 | 18,560 | Mixed |
| American Century | 86,962 | 0 | 0 | 0 | For |
| Goldman Sachs | 64,757 | 0 | 0 | 0 | For |
| TIAA | 58,674 | 0 | 0 | 0 | For |
| Jackson National | 45,538 | 0 | 0 | 0 | For |
| Aberdeen | 44,768 | 0 | 0 | 0 | For |
| Invesco | 38,541 | 0 | 0 | 0 | For |
| JPMorgan | 38,357 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 38,307 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 36,216 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 33,207 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 28,070 | 0 | 0 | 0 | For |
| Lincoln Financial | 25,250 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 24,622 | 0 | 0 | 0 | For |
Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: Marcio Souza
Praxis Precision Medicines, Inc.’s own tally for this item (“Elect Director: Marcio Souza”): 24,771,396 for, 136,868 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 90 asset managers below reported 9,304,326 for, 33,073 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,248,556 | 0 | 0 | 0 | For |
| Vanguard | 2,029,871 | 0 | 0 | 2,356 | For |
| BlackRock | 1,179,030 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,105,598 | 0 | 0 | 0 | For |
| T. Rowe Price | 559,689 | 0 | 0 | 0 | For |
| State Street | 333,482 | 0 | 0 | 0 | For |
| Charles Schwab | 216,365 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 211,007 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 140,900 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 120,135 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 119,129 | 0 | 0 | 0 | For |
| Equitable | 87,801 | 0 | 0 | 0 | For |
| American Century | 86,962 | 0 | 0 | 0 | For |
| Goldman Sachs | 64,757 | 0 | 0 | 0 | For |
| TIAA | 58,674 | 0 | 0 | 0 | For |
| Jackson National | 45,538 | 0 | 0 | 0 | For |
| Aberdeen | 44,768 | 0 | 0 | 0 | For |
| Invesco | 38,541 | 0 | 0 | 0 | For |
| JPMorgan | 38,357 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 38,307 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 36,216 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 33,207 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 28,070 | 0 | 0 | 0 | For |
| Lincoln Financial | 25,250 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 24,622 | 0 | 0 | 0 | For |
Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.
Combines 5 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: To elect the Class III Directors to serve until the 2029 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified: William Young
Praxis Precision Medicines, Inc.’s own tally for this item (“Elect Director: William Young”): 21,293,535 for, 3,614,729 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 90 asset managers below reported 8,404,448 for, 932,942 withheld, 9 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,248,556 | 0 | 0 | 0 | For |
| Vanguard | 1,965,625 | 0 | 9 | 66,593 | For |
| BlackRock | 1,179,030 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,083,121 | 0 | 0 | 22,477 | For |
| T. Rowe Price | 559,689 | 0 | 0 | 0 | For |
| State Street | 333,482 | 0 | 0 | 0 | For |
| Charles Schwab | 216,365 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 211,007 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 11,089 | 0 | 0 | 129,811 | Mixed |
| FRANKLIN STRATEGIC SERIES | 120,135 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 119,129 | Withhold |
| Equitable | 69,241 | 0 | 0 | 18,560 | Mixed |
| American Century | 0 | 0 | 0 | 86,962 | Withhold |
| Goldman Sachs | 1,158 | 0 | 0 | 63,599 | Withhold |
| TIAA | 58,674 | 0 | 0 | 0 | For |
| Jackson National | 16,294 | 0 | 0 | 29,244 | Mixed |
| Aberdeen | 0 | 0 | 0 | 44,768 | Withhold |
| Invesco | 38,541 | 0 | 0 | 0 | For |
| JPMorgan | 38,357 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 38,307 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 36,216 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 33,207 | Withhold |
| MERIDIAN FUND INC | 0 | 0 | 0 | 28,070 | Withhold |
| Lincoln Financial | 19,366 | 0 | 0 | 5,884 | Mixed |
| JANUS ASPEN SERIES | 24,622 | 0 | 0 | 0 | For |
Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.
Combines 16 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: To approve, on an advisory (non-binding) basis, the compensation of the named executive officers as disclosed in the Company's proxy statement for the 2026 Annual Meeting of Stockholders pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion.
Praxis Precision Medicines, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 24,054,017 for, 824,318 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of the Company's named executive officers, with the votes cast as follows:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,248,556 | 0 | 0 | 0 | For |
| Vanguard | 2,032,226 | 1 | 0 | 0 | For |
| BlackRock | 1,179,030 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,105,598 | 0 | 0 | 0 | For |
| T. Rowe Price | 559,689 | 0 | 0 | 0 | For |
| State Street | 333,482 | 0 | 0 | 0 | For |
| Charles Schwab | 216,365 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 211,007 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 140,900 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 120,135 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 119,129 | 0 | 0 | 0 | For |
| Equitable | 87,801 | 0 | 0 | 0 | For |
| American Century | 0 | 86,962 | 0 | 0 | Against |
| Goldman Sachs | 64,757 | 0 | 0 | 0 | For |
| TIAA | 58,674 | 0 | 0 | 0 | For |
| Jackson National | 45,538 | 0 | 0 | 0 | For |
| Aberdeen | 44,768 | 0 | 0 | 0 | For |
| Invesco | 0 | 38,541 | 0 | 0 | Against |
| JPMorgan | 38,357 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 38,307 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 36,216 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 33,207 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 28,070 | 0 | 0 | 0 | For |
| Lincoln Financial | 25,250 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 24,622 | 0 | 0 | 0 | For |
Fund voting reports, all 90 managers: 9,207,172 for, 134,080 against, 147 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 6,677,450 | 5,542 | 0 | 0 | For |
| Fidelity | 2,102,468 | 0 | 0 | 0 | For |
| Orbis Allan Gray Ltd | 2,077,447 | 0 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,752,527 | 0 | 0 | 0 | For |
| BlackRock | 911,013 | 5,632 | 0 | 0 | For |
| State Street | 848,956 | 4,850 | 0 | 0 | For |
| T. Rowe Price | 839,674 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 650,880 | 0 | 0 | 0 | For |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 643,067 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 585,597 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 554,722 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 347,724 | 0 | 0 | 0 | For |
| Hood River Capital Management LLC | 346,987 | 0 | 0 | 0 | For |
| Vivo Capital, LLC | 338,895 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 335,132 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 331,981 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 271,257 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 264,117 | 0 | 0 | 0 | For |
| AustralianSuper Pty Ltd | 0 | 227,786 | 0 | 0 | Against |
| Charles Schwab | 216,451 | 0 | 0 | 0 | For |
| Vanguard | 209,875 | 0 | 0 | 0 | For |
| Northern Trust | 201,585 | 1,018 | 0 | 0 | For |
| Aberdeen | 172,484 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 165,510 | 0 | 0 | 0 | For |
| Woodline Partners LP | 157,886 | 0 | 0 | 0 | For |
Institutional-manager reports, all 240 managers: 22,941,678 for, 644,159 against, 882 abstained, 102 not voted. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Praxis Precision Medicines, Inc.’s own tally for this item (“2. Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm”): 26,667,376 for, 39,285 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of Appointment of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31…”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 90 asset managers below reported 9,337,253 for, 147 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 2,248,556 | 0 | 0 | 0 | For |
| Vanguard | 2,032,228 | 0 | 0 | 0 | For |
| BlackRock | 1,179,030 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,105,598 | 0 | 0 | 0 | For |
| T. Rowe Price | 559,689 | 0 | 0 | 0 | For |
| State Street | 333,482 | 0 | 0 | 0 | For |
| Charles Schwab | 216,365 | 0 | 0 | 0 | For |
| Manager Directed Portfolios | 211,007 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 140,900 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 120,135 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 119,129 | 0 | 0 | 0 | For |
| Equitable | 87,801 | 0 | 0 | 0 | For |
| American Century | 86,962 | 0 | 0 | 0 | For |
| Goldman Sachs | 64,757 | 0 | 0 | 0 | For |
| TIAA | 58,674 | 0 | 0 | 0 | For |
| Jackson National | 45,538 | 0 | 0 | 0 | For |
| Aberdeen | 44,768 | 0 | 0 | 0 | For |
| Invesco | 38,541 | 0 | 0 | 0 | For |
| JPMorgan | 38,357 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 38,307 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 36,216 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 33,207 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 28,070 | 0 | 0 | 0 | For |
| Lincoln Financial | 25,250 | 0 | 0 | 0 | For |
| JANUS ASPEN SERIES | 24,622 | 0 | 0 | 0 | For |
Showing the 25 largest of 90 asset managers. See all 90 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 27,859,514 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 8.07% |
| 2 | Vanguard | 7.29% |
| 3 | BlackRock | 4.23% |
| 4 | JANUS INVESTMENT FUND | 3.97% |
| 5 | T. Rowe Price | 2.01% |
| 6 | State Street | 1.20% |
| 7 | Charles Schwab | 0.78% |
| 8 | Manager Directed Portfolios | 0.76% |
| 9 | Bridge Builder Trust | 0.51% |
| 10 | FRANKLIN STRATEGIC SERIES | 0.43% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 23.99% |
| 2 | Fidelity | 7.55% |
| 3 | Orbis Allan Gray Ltd | 7.46% |
| 4 | PERCEPTIVE ADVISORS LLC | 6.29% |
| 5 | BlackRock | 3.29% |
| 6 | State Street | 3.06% |
| 7 | T. Rowe Price | 3.01% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 2.34% |
| 9 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.31% |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.10% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Janus Henderson Group | 9.92% | DEF14A |
| BlackRock | 8.35% | 13F |
| FMR (Fidelity) | 7.76% | 13F |
| Entities affiliated with Perceptive Advisors | 7.16% | DEF14A |
| Perceptive Advisors LLC | 7.16% | 13G |
| Baker Bros. Advisors LP | 6.29% | 13G |
| Entities affiliated with Point72 | 5.63% | DEF14A |
| ORBIS INVESTMENT MANAGEMENT LTD | 5.48% | 13G |
| Vanguard Group | 5.24% | 13F |
| Morgan Stanley | 3.19% | 13F |
Percentages above are of 27,859,514 shares outstanding, as reported by Praxis Precision Medicines, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Praxis Precision Medicines, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At Praxis Precision Medicines, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 303 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 2,129 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory (non-binding) basis, the compensation of the named executive… — Praxis Precision Medicines, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Praxis Precision Medicines, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.
Praxis Precision Medicines, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.